Microvillus Length Biomarker for Predicting IBD Therapy Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory bowel disease (IBD) lack objective criteria for selecting therapies, leading to a trial-and-error approach that is inefficient and potentially ineffective.
Innovation Solution
The use of microvillus length as a mucosal marker to predict a subject's responsiveness to anti-inflammatory bowel disease treatments, such as anti-IL-12/23, anti-α4β7 integrin, and anti-TNFα therapies, by measuring microvillus length in a biological sample and comparing it to predetermined values.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a stepwise approach to medication is used to monitor patient responsiveness, then the treatment safety is improved, but the treatment time and efficiency deteriorate
Solution Approach 1:
The patent measures microvillus length before initiating IBD treatment to predict patient responsiveness in advance. This preliminary assessment allows clinicians to select the most appropriate therapy from the outset, avoiding the need for sequential trial-and-error treatments while maintaining safety through predictive biomarker-guided decision-making.
2Adaptability or versatility
If no objective criteria are used for therapy selection, then the treatment flexibility is maintained, but the treatment effectiveness deteriorates
Solution Approach 1:
The patent introduces microvillus length as a quantitative biomarker parameter to guide therapy selection. By measuring this specific physical parameter, the method provides an objective criterion that enhances treatment effectiveness while preserving flexibility, as clinicians can still adapt treatment based on the quantitative results and patient-specific factors.
3Reliability
If multiple biologic therapies are tried sequentially, then the probability of finding an effective treatment increases, but the loss of time and resources increases
Solution Approach 1:
The patent performs preliminary measurement of microvillus length to predict which biologic therapy will be most effective for each patient before treatment begins. This advance assessment allows for direct selection of the optimal therapy, eliminating the need for sequential trials and significantly improving treatment efficiency while maintaining high success rates.
Solution Approach 2:
The patent uses microvillus length as an intermediary biomarker that mediates between patient characteristics and therapy selection. This intermediary parameter provides an objective basis for matching patients to appropriate biologic therapies, reducing the need for multiple treatment attempts and improving overall productivity in IBD management.
Data Source
AI summary
The present disclosure provides methods of selecting a treatment for an inflammatory bowel disease in a subject. In particular, using an indicator of epithelial absorption and metabolism the present disclosure provides method for determining the likelihood a subject is responsive or non-responsive to an inflammatory bowel disease therapeutic agent. The method includes providing a baseline measurement of a microvillus length in the small intestine of a subject, selecting a treatment for the subject according to a treatment criteria, and administering the treatment to the subject.